Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 73

1.

Clinical and biological features of PTPN2-deleted adult and pediatric T-cell acute lymphoblastic leukemia.

Alcantara M, Simonin M, Lhermitte L, Touzart A, Dourthe ME, Latiri M, Grardel N, Cayuela JM, Chalandon Y, Graux C, Dombret H, Ifrah N, Petit A, Macintyre E, Baruchel A, Boissel N, Asnafi V.

Blood Adv. 2019 Jul 9;3(13):1981-1988. doi: 10.1182/bloodadvances.2018028993.

2.

Microenvironment tailors nTreg structure and function.

Schiavon V, Duchez S, Branchtein M, How-Kit A, Cassius C, Daunay A, Shen Y, Dubanchet S, Colisson R, Vanneaux V, Pruvost A, Roucairol C, Setterblad N, Bouaziz JD, Boissier MC, Semerano L, Graux C, Bensussan A, Burny A, Gallo R, Zagury D, Le Buanec H.

Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6298-6307. doi: 10.1073/pnas.1812471116. Epub 2019 Mar 7.

3.

Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres.

Poirel HA, Vanspauwen M, Macq G, De Geyndt A, Maertens J, Willems E, Selleslag D, Poiré X, Theunissen K, Graux C, Kerre T, Zachée P, Meuleman N, De Becker A, Verlinden A, Van Obbergh F, Schuermans C, De Wilde V, Jaspers A, Pranger D, Deeren D, Van Riet I, Vaes E, Beguin Y; Belgian Transplant Registry and the Belgian Haematological Society’s Transplant committee.

Bone Marrow Transplant. 2019 Jan 29. doi: 10.1038/s41409-019-0458-8. [Epub ahead of print]

PMID:
30696999
4.

Epigenetic Silencing Affects l-Asparaginase Sensitivity and Predicts Outcome in T-ALL.

Touzart A, Lengliné E, Latiri M, Belhocine M, Smith C, Thomas X, Spicuglia S, Puthier D, Pflumio F, Leguay T, Graux C, Chalandon Y, Huguet F, Leprêtre S, Ifrah N, Dombret H, Macintyre E, Hunault M, Boissel N, Asnafi V.

Clin Cancer Res. 2019 Apr 15;25(8):2483-2493. doi: 10.1158/1078-0432.CCR-18-1844. Epub 2019 Jan 18.

PMID:
30659025
5.

DNMT3A mutation is associated with increased age and adverse outcome in adult T-cell acute lymphoblastic leukemia.

Bond J, Touzart A, Leprêtre S, Graux C, Bargetzi M, Lhermitte L, Hypolite G, Leguay T, Hicheri Y, Guillerm G, Bilger K, Lhéritier V, Hunault M, Huguet F, Chalandon Y, Ifrah N, Macintyre E, Dombret H, Asnafi V, Boissel N.

Haematologica. 2019 Aug;104(8):1617-1625. doi: 10.3324/haematol.2018.197848. Epub 2019 Jan 17.

6.

Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients.

Huls G, Chitu DA, Havelange V, Jongen-Lavrencic M, van de Loosdrecht AA, Biemond BJ, Sinnige H, Hodossy B, Graux C, Kooy RVM, de Weerdt O, Breems D, Klein S, Kuball J, Deeren D, Terpstra W, Vekemans MC, Ossenkoppele GJ, Vellenga E, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON).

Blood. 2019 Mar 28;133(13):1457-1464. doi: 10.1182/blood-2018-10-879866. Epub 2019 Jan 10.

PMID:
30630862
7.

PAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome.

Passet M, Boissel N, Sigaux F, Saillard C, Bargetzi M, Ba I, Thomas X, Graux C, Chalandon Y, Leguay T, Lengliné E, Konopacki J, Quentin S, Delabesse E, Lafage-Pochitaloff M, Pastoret C, Grardel N, Asnafi V, Lhéritier V, Soulier J, Dombret H, Clappier E; Group for Research on Adult ALL (GRAALL).

Blood. 2019 Jan 17;133(3):280-284. doi: 10.1182/blood-2018-10-882142. Epub 2018 Dec 3. No abstract available.

PMID:
30510083
8.

Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study.

Bouvy C, Wannez A, George F, Graux C, Chatelain C, Dogné JM.

Biomark Cancer. 2018 Jun 18;10:1179299X18781095. doi: 10.1177/1179299X18781095. eCollection 2018.

9.

The eGVHD App has the potential to improve the accuracy of graft-versus-host disease assessment: a multicenter randomized controlled trial.

Schoemans HM, Goris K, Van Durm R, Fieuws S, De Geest S, Pavletic SZ, Im A, Wolff D, Lee SJ, Greinix H, Duarte RF, Poiré X, Selleslag D, Lewalle P, Kerre T, Graux C, Baron F, Maertens JA, Dobbels F; EBMT Transplantation Complications Working party.

Haematologica. 2018 Oct;103(10):1698-1707. doi: 10.3324/haematol.2018.190777. Epub 2018 Jun 14.

10.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM.

N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863.

11.

BCR-ABL Tyrosine Kinase Inhibitors: Which Mechanism(s) May Explain the Risk of Thrombosis?

Haguet H, Douxfils J, Chatelain C, Graux C, Mullier F, Dogné JM.

TH Open. 2018 Feb 14;2(1):e68-e88. doi: 10.1055/s-0038-1624566. eCollection 2018 Jan. Review.

12.

Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.

Gökbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Brüggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC.

Blood. 2018 Apr 5;131(14):1522-1531. doi: 10.1182/blood-2017-08-798322. Epub 2018 Jan 22. Erratum in: Blood. 2019 Jun 13;133(24):2625.

13.

Impact of cytogenetic abnormalities in adults with Ph-negative B-cell precursor acute lymphoblastic leukemia.

Lafage-Pochitaloff M, Baranger L, Hunault M, Cuccuini W, Lefebvre C, Bidet A, Tigaud I, Eclache V, Delabesse E, Bilhou-Nabéra C, Terré C, Chapiro E, Gachard N, Mozziconacci MJ, Ameye G, Porter S, Grardel N, Béné MC, Chalandon Y, Graux C, Huguet F, Lhéritier V, Ifrah N, Dombret H; Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL).

Blood. 2017 Oct 19;130(16):1832-1844. doi: 10.1182/blood-2017-05-783852. Epub 2017 Aug 8.

14.

Early Response-Based Therapy Stratification Improves Survival in Adult Early Thymic Precursor Acute Lymphoblastic Leukemia: A Group for Research on Adult Acute Lymphoblastic Leukemia Study.

Bond J, Graux C, Lhermitte L, Lara D, Cluzeau T, Leguay T, Cieslak A, Trinquand A, Pastoret C, Belhocine M, Spicuglia S, Lheritier V, Leprêtre S, Thomas X, Huguet F, Ifrah N, Dombret H, Macintyre E, Boissel N, Asnafi V.

J Clin Oncol. 2017 Aug 10;35(23):2683-2691. doi: 10.1200/JCO.2016.71.8585. Epub 2017 Jun 12.

PMID:
28605290
15.

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.

Garcia-Manero G, Sekeres MA, Egyed M, Breccia M, Graux C, Cavenagh JD, Salman H, Illes A, Fenaux P, DeAngelo DJ, Stauder R, Yee K, Zhu N, Lee JH, Valcarcel D, MacWhannell A, Borbenyi Z, Gazi L, Acharyya S, Ide S, Marker M, Ottmann OG.

Leukemia. 2017 Dec;31(12):2799-2806. doi: 10.1038/leu.2017.159. Epub 2017 May 26.

16.

Adult T-type lymphoblastic lymphoma: Treatment advances and prognostic indicators.

Lepretre S, Graux C, Touzart A, Macintyre E, Boissel N.

Exp Hematol. 2017 Jul;51:7-16. doi: 10.1016/j.exphem.2017.04.002. Epub 2017 Apr 12. Review.

PMID:
28412288
17.

Retrospective chart review of hospitalizations and costs associated with the treatment of adults with Philadelphia-negative B-cell relapsed or refractory acute lymphoblastic leukemia in Belgium.

Maertens J, Graux C, Breems D, Havelange V, Wittnebel S, Strens D, Hoefkens C.

Acta Clin Belg. 2017 Dec;72(6):429-433. doi: 10.1080/17843286.2017.1314091. Epub 2017 Apr 13.

PMID:
28406385
18.

Procoagulant activity of extracellular vesicles as a potential biomarker for risk of thrombosis and DIC in patients with acute leukaemia.

Gheldof D, Haguet H, Dogné JM, Bouvy C, Graux C, George F, Sonet A, Chatelain C, Chatelain B, Mullier F.

J Thromb Thrombolysis. 2017 Feb;43(2):224-232. doi: 10.1007/s11239-016-1471-z.

PMID:
28074413
19.

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).

Blood. 2017 Mar 23;129(12):1636-1645. doi: 10.1182/blood-2016-10-740613. Epub 2017 Jan 3.

20.

The clinical relevance of imatinib plasma trough concentrations in chronic myeloid leukemia. A Belgian study.

Van Obbergh F, Knoops L, Devos T, Beguin Y, Graux C, Benghiat F, Kargar-Samani K, Bauwens D, Efira A, Dubois C, Springael C, Montfort L, Connerotte T, Capron A, Delannoy A, Wallemacq P.

Clin Biochem. 2017 May;50(7-8):452-454. doi: 10.1016/j.clinbiochem.2016.12.006. Epub 2016 Dec 22.

21.

Hematopoietic stem cell apheresis in the context of a related allogeneic transplant for acute myeloid leukemia: an unexpected outcome, medical emergency and ethical issue.

Bourgeois M, Sonet A, Botson F, Graux C, Fabry A, André M, Deneys V.

Haematologica. 2017 Mar;102(3):e115-e116. doi: 10.3324/haematol.2016.159285. Epub 2016 Dec 7. No abstract available.

22.

Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis.

Haguet H, Douxfils J, Mullier F, Chatelain C, Graux C, Dogné JM.

Expert Opin Drug Saf. 2017 Jan;16(1):5-12. Epub 2016 Nov 28. Review.

PMID:
27852118
23.

Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival: A Systematic Review and Meta-analysis.

Douxfils J, Haguet H, Mullier F, Chatelain C, Graux C, Dogné JM.

JAMA Oncol. 2016 May 1;2(5):625-632. doi: 10.1001/jamaoncol.2015.5932.

PMID:
26847662
24.

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.

Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, Theobald M, Graux C, Kuball J, Schouten HC, Pabst T, Löwenberg B, Ossenkoppele G, Vellenga E, Cornelissen JJ; HOVON and SAKK Leukemia Groups.

Lancet Haematol. 2015 Oct;2(10):e427-36. doi: 10.1016/S2352-3026(15)00148-9. Epub 2015 Sep 18.

PMID:
26686044
25.

Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.

Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, Lamy T, Béné MC, Raffoux E, Huguet F, Chevallier P, Bologna S, Bouabdallah R, Benichou J, Brière J, Moreau A, Tallon-Simon V, Seris S, Graux C, Asnafi V, Ifrah N, Macintyre E, Dombret H.

J Clin Oncol. 2016 Feb 20;34(6):572-80. doi: 10.1200/JCO.2015.61.5385. Epub 2015 Dec 7.

26.

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.

Al Assaf C, Van Obbergh F, Billiet J, Lierman E, Devos T, Graux C, Hervent AS, Emmerechts J, Tousseyn T, De Paepe P, Papadopoulos P, Michaux L, Vandenberghe P.

Haematologica. 2015 Jul;100(7):893-7. doi: 10.3324/haematol.2014.118299. Epub 2015 May 1.

27.

Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Following Flu-TBI versus TLI-ATG Conditioning.

Hannon M, Beguin Y, Ehx G, Servais S, Seidel L, Graux C, Maertens J, Kerre T, Daulne C, de Bock M, Fillet M, Ory A, Willems E, Gothot A, Humblet-Baron S, Baron F.

Clin Cancer Res. 2015 Jul 15;21(14):3131-9. doi: 10.1158/1078-0432.CCR-14-3374. Epub 2015 Mar 16.

28.

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.

Baron F, Zachée P, Maertens J, Kerre T, Ory A, Seidel L, Graux C, Lewalle P, Van Gelder M, Theunissen K, Willems E, Emonds MP, De Becker A, Beguin Y.

J Hematol Oncol. 2015 Feb 6;8:4. doi: 10.1186/s13045-014-0098-9.

29.

Cycling hypoxia induces a specific amplified inflammatory phenotype in endothelial cells and enhances tumor-promoting inflammation in vivo.

Tellier C, Desmet D, Petit L, Finet L, Graux C, Raes M, Feron O, Michiels C.

Neoplasia. 2015 Jan;17(1):66-78. doi: 10.1016/j.neo.2014.11.003.

30.

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia.

Dhédin N, Huynh A, Maury S, Tabrizi R, Beldjord K, Asnafi V, Thomas X, Chevallier P, Nguyen S, Coiteux V, Bourhis JH, Hichri Y, Escoffre-Barbe M, Reman O, Graux C, Chalandon Y, Blaise D, Schanz U, Lhéritier V, Cahn JY, Dombret H, Ifrah N; GRAALL group.

Blood. 2015 Apr 16;125(16):2486-96; quiz 2586. doi: 10.1182/blood-2014-09-599894. Epub 2015 Jan 13.

31.

Safety and efficacy of azacitidine in Belgian patients with high-risk myelodysplastic syndromes, acute myeloid leukaemia, or chronic myelomonocytic leukaemia: results of a real-life, non-interventional post-marketing survey.

Beguin Y, Selleslag D, Meers S, Graux C, Bries G, Deeren D, Vrelust I, Ravoet C, Theunissen K, Voelter V, Potier H, Trullemans F, Noens L, Mineur P.

Acta Clin Belg. 2015 Feb;70(1):34-43. doi: 10.1179/2295333714Y.0000000102. Epub 2014 Dec 2.

32.

Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years.

Cornelissen JJ, Versluis J, Passweg JR, van Putten WL, Manz MG, Maertens J, Beverloo HB, Valk PJ, van Marwijk Kooy M, Wijermans PW, Schaafsma MR, Biemond BJ, Vekemans MC, Breems DA, Verdonck LF, Fey MF, Jongen-Lavrencic M, Janssen JJ, Huls G, Kuball J, Pabst T, Graux C, Schouten HC, Gratwohl A, Vellenga E, Ossenkoppele G, Löwenberg B; HOVON; SAKK Leukemia Groups.

Leukemia. 2015 May;29(5):1041-50. doi: 10.1038/leu.2014.332. Epub 2014 Nov 27.

PMID:
25428261
33.

Adequate iron chelation therapy for at least six months improves survival in transfusion-dependent patients with lower risk myelodysplastic syndromes.

Delforge M, Selleslag D, Beguin Y, Triffet A, Mineur P, Theunissen K, Graux C, Trullemans F, Boulet D, Van Eygen K, Noens L, Van Steenweghen S, Lemmens J, Pierre P, D'hondt R, Ferrant A, Deeren D, Van De Velde A, Wynendaele W, André M, De Bock R, Efira A, Breems D, Deweweire A, Geldhof K, Pluymers W, Harrington A, MacDonald K, Abraham I, Ravoet C.

Leuk Res. 2014 May;38(5):557-63. doi: 10.1016/j.leukres.2014.02.003. Epub 2014 Feb 14.

PMID:
24661630
34.

Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1.

Al Assaf C, Lierman E, Devos T, Billiet J, Graux C, Papadopoulos P, Vandenberghe P.

Br J Haematol. 2014 Jun;165(5):734-7. doi: 10.1111/bjh.12790. Epub 2014 Feb 26. No abstract available.

35.

Management of myelodysplastic syndromes in adults: guidelines from the Belgian Haematological Society.

Meers S, Breems D, Bries G, Delforge M, Graux C, Ravoet C, Selleslag D, Noens L; Belgian Haematological Society.

Acta Clin Belg. 2013 Jul-Aug;68(4):253-62.

PMID:
24455794
36.

Non-IG aberrations of FOXP1 in B-cell malignancies lead to an aberrant expression of N-truncated isoforms of FOXP1.

Rouhigharabaei L, Finalet Ferreiro J, Tousseyn T, van der Krogt JA, Put N, Haralambieva E, Graux C, Maes B, Vicente C, Vandenberghe P, Cools J, Wlodarska I.

PLoS One. 2014 Jan 9;9(1):e85851. doi: 10.1371/journal.pone.0085851. eCollection 2014.

37.

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Terwijn M, van Putten WL, Kelder A, van der Velden VH, Brooimans RA, Pabst T, Maertens J, Boeckx N, de Greef GE, Valk PJ, Preijers FW, Huijgens PC, Dräger AM, Schanz U, Jongen-Lavrecic M, Biemond BJ, Passweg JR, van Gelder M, Wijermans P, Graux C, Bargetzi M, Legdeur MC, Kuball J, de Weerdt O, Chalandon Y, Hess U, Verdonck LF, Gratama JW, Oussoren YJ, Scholten WJ, Slomp J, Snel AN, Vekemans MC, Löwenberg B, Ossenkoppele GJ, Schuurhuis GJ.

J Clin Oncol. 2013 Nov 1;31(31):3889-97. doi: 10.1200/JCO.2012.45.9628. Epub 2013 Sep 23.

PMID:
24062400
38.

Unusual cause of severe anaemia in a patient with metastatic haemangiopericytoma.

Vanhaudenarde V, Duck L, Mazzeo F, Graux C, Jamar F, Coche E, Galant C, Machiels JP.

Acta Clin Belg. 2013 Mar-Apr;68(2):120-3.

PMID:
23967721
39.

A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies.

Graux C, Sonet A, Maertens J, Duyster J, Greiner J, Chalandon Y, Martinelli G, Hess D, Heim D, Giles FJ, Kelly KR, Gianella-Borradori A, Longerey B, Asatiani E, Rejeb N, Ottmann OG.

Leuk Res. 2013 Sep;37(9):1100-6. doi: 10.1016/j.leukres.2013.04.025. Epub 2013 Jun 5.

PMID:
23746966
40.

Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and the Swiss Group for Clinical Cancer Research (SAKK).

Ossenkoppele GJ, Stussi G, Maertens J, van Montfort K, Biemond BJ, Breems D, Ferrant A, Graux C, de Greef GE, Halkes CJ, Hoogendoorn M, Hollestein RM, Jongen-Lavrencic M, Levin MD, van de Loosdrecht AA, van Marwijk Kooij M, van Norden Y, Pabst T, Schouten HC, Vellenga E, Verhoef GE, de Weerdt O, Wijermans P, Passweg JR, Löwenberg B.

Blood. 2012 Dec 6;120(24):4706-11. doi: 10.1182/blood-2012-04-420596. Epub 2012 Oct 9.

41.

A case of therapy-related myeloid neoplasm in a patient with Crohn's disease treated with azathioprine.

Mullier F, Rahier JF, Maignen F, Cornet Y, Graux C, Chatelain C, Chatelain B, Dogne JM.

Acta Haematol. 2012;128(1):1-6. doi: 10.1159/000337046. Epub 2012 May 4. Review.

PMID:
22572218
42.

Rearrangement of NOTCH1 or BCL3 can independently trigger progression of CLL.

De Keersmaecker K, Michaux L, Bosly A, Graux C, Ferreiro JF, Vandenberghe P, Cools J, Wlodarska I.

Blood. 2012 Apr 19;119(16):3864-6. doi: 10.1182/blood-2011-10-388124. No abstract available.

43.

Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine.

Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans MC, Biemond B, Sonneveld P, Passweg J, Verdonck L, Legdeur MC, Theobald M, Jacky E, Bargetzi M, Maertens J, Ossenkoppele GJ, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German AML Study Group (AMLSG); Swiss Collaborative Group for Clinical Cancer Research (SAKK).

Blood. 2012 Jun 7;119(23):5367-73. doi: 10.1182/blood-2011-11-389841. Epub 2012 Mar 15.

44.

[Current management of myelodysplastic syndromes].

Caers J, Bonnet C, Graux C, De Prijck B, Beguin Y.

Rev Med Suisse. 2011 Aug 31;7(306):1634, 1636-8, 1640-3. French.

45.

Autologous peripheral blood stem cell transplantation for acute myeloid leukemia.

Vellenga E, van Putten W, Ossenkoppele GJ, Verdonck LF, Theobald M, Cornelissen JJ, Huijgens PC, Maertens J, Gratwohl A, Schaafsma R, Schanz U, Graux C, Schouten HC, Ferrant A, Bargetzi M, Fey MF, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); Swiss Group for Clinical Cancer Research Collaborative Group (SAKK).

Blood. 2011 Dec 1;118(23):6037-42. doi: 10.1182/blood-2011-07-370247. Epub 2011 Sep 27.

46.

Cytarabine dose for acute myeloid leukemia.

Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group.

N Engl J Med. 2011 Mar 17;364(11):1027-36. doi: 10.1056/NEJMoa1010222.

47.

Biology of acute lymphoblastic leukemia (ALL): clinical and therapeutic relevance.

Graux C.

Transfus Apher Sci. 2011 Apr;44(2):183-9. doi: 10.1016/j.transci.2011.01.009. Epub 2011 Feb 25. Review.

PMID:
21354375
48.

[Establishing a pilot project for therapeutic education in nephrology].

Graux C, Dousseaux MP, Grimault M, Giraud M, Deray G, Isnard-Bagnis C, Jean M, Bouffette L, Fernandez C, Tourette-Turgis C.

Rev Infirm. 2011 Feb;(168):35-7. French. No abstract available.

PMID:
21341448
49.

Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.

Delforge M, Selleslag D, Triffet A, Mineur P, Bries G, Graux C, Trullemans F, MacDonald K, Abraham I, Pluymers W, Ravoet C.

Ann Hematol. 2011 Jun;90(6):655-66. doi: 10.1007/s00277-011-1164-9. Epub 2011 Feb 12.

PMID:
21318574
50.

CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients.

Arnaud L, Hervier B, Néel A, Hamidou MA, Kahn JE, Wechsler B, Pérez-Pastor G, Blomberg B, Fuzibet JG, Dubourguet F, Marinho A, Magnette C, Noel V, Pavic M, Casper J, Beucher AB, Costedoat-Chalumeau N, Aaron L, Salvatierra J, Graux C, Cacoub P, Delcey V, Dechant C, Bindi P, Herbaut C, Graziani G, Amoura Z, Haroche J.

Blood. 2011 Mar 10;117(10):2778-82. doi: 10.1182/blood-2010-06-294108. Epub 2011 Jan 14.

Supplemental Content

Support Center